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A B S T R A C T
Purpose: Glioblastoma multiforme (GBM) is the most lethal type of primary brain tumor, and patients
that undergo the maximum tumor resection that is safely possible and standard radiochemotherapy
only achieve a median survival time of 14.6 months. Several clinical studies have reported that valproic
acid could prolong survival of GBM patients. However, the results of these studies are inconsistent. We
examined relevant studies and conducted a meta-analysis to assess the effects of VPA on survival times
and recurrence.
Methods: A bibliographic search was performed in the EMBASE, MEDLINE, ClinicalTrials.gov and
Cochrane Central Register of the Controlled Trials databases to identify potentially relevant articles or
conference abstracts that investigated the effects of VPA on the outcome of glioma patients. Five
observational studies were included.
Results: Pooled estimates of the hazard ratio (HR) and 95% conﬁdence intervals (CI) were calculated. Our
meta-analysis conﬁrmed the beneﬁt of using VPA (HR, 0.56; 95% CI, 0.44–0.71). Sub-group analysis
shows that patients treated with VPA had a hazard ratio of 0.74 with a 95% conﬁdence interval of 0.59–
0.94 vs. patients treated by other-AEDs and a hazard ratio of 0.66 with a 95% conﬁdence interval of 0.52–
0.84 vs. patients treated by administration of non-AEDs. No heterogeneity was observed in the subset
analysis.
Conclusion: The results of our study suggest that glioblastoma patients may experience prolonged
survival due to VPA administration. Sub-analysis conﬁrmed the beneﬁt of VPA use compared to a non-
AEDs group and an other-AEDs group. Further RCTs of this subject should be performed.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Glioblastoma multiforme (GBM) is the most lethal and most
frequent type of astrocytic brain tumor in adults.1 It is a malignant,
highly recurrent intracranial neoplasm with a rapidly progressive
and fatal outcome. Patients who undergo the maximum tumor
resection that is safely possible and standard radiochemotherapy
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than 10%.2 Glioma-associated seizures (GAS) frequently occur
among glioma patients. Approximately 30%–50% of GBM patients
will experience seizure activity before surgery, and 6%–45%
experience seizures post-diagnosis.3 However, it has been reported
that GBM patients with a history of seizures will have a better
prognosis than patients without seizures, which raises questions
about whether the antiepileptic drugs, especially those with anti-
tumor functions, play a role in this process.
Valproic acid (VPA) has evolved beyond its original use in the
1960s, as an established anticonvulsant drug and mood stabilizer,
into an anticancer drug.4 Preclinical studies within the last decade
have suggested that VPA and its analogs could affect tumor cells in
many respects, such as inhibition of a subset of histone
deacetylases (HDAC) and cellular kinases, which could affect gene
transcription through histone hyperacetylation, DNA hypomethy-
lation, and modulation of the MAPK signaling pathway.5 As aserved.
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differentiation and apoptosis in diverse types of tumor cells. Some
clinical studies have reported the outcome of GBM patients with
valproic acid for seizure prophylaxis or treatment, and it appears
that most, but not all, of these reports have suggested that VPA
could prolong overall survival in GBM patients.6 However, the
combination of the results of these studies in our meta-analysis
increases the statistical power and may provide sufﬁcient
information to show a credible survival beneﬁt of VPA treatment.
Therefore, we conducted a survival analysis for valproic acid
treatment of adult glioblastoma multiforme. Using meta-analysis,
we initiated time-to-event analyses, which are extremely impor-
tant for malignant tumors such as glioblastoma multiforme. Novel




In February 2014, a bibliographic search was performed in the
EMBASE, MEDLINE, ClinicalTrials.gov and Cochrane Central Regis-
ter of Controlled Trials databases to identify potentially relevant
articles or conference abstracts that reported the outcome of
patients diagnosed with glioblastoma multiforme, and we initiated
the survival analysis of patients treated with or without valproic
acid. The search was limited to studies written in English. Two
investigators (Y.Y and W.X) independently evaluated papers with
respect to the inclusion and exclusion criteria, and any controver-
sies were settled by discussion and consensus. The references
contained in the identiﬁed trials were also examined to identify
any other relevant published or unpublished articles. We used
combinations of the following search terms: glioma, valproic acid,
outcome and brain tumor (details of the search criteria are
provided in Supplemental ﬁle 1).
2.2. Inclusion and exclusion criteria
The inclusion criteria were as follows:
(a) Because drug use may involve ethical issues and limited or no
RCTs, all comparative studies (i.e., trial, cohort, case–control
and observational studies) of the relevant AEDs were included.
(b) The glioma cases were histologically conﬁrmed, and all
included patients had undergone surgery or biopsy; the age
of all patients was >17 years.
(c) The articles provided survival status, hazard ratio (HR), and 95%
conﬁdence intervals (CIs) or information sufﬁcient to calculate
these variables from the raw data (including distinct Kaplan–
Meier survival curves, number of patients of the research and
control team, and follow up time).
We excluded studies for the following reasons:
(i) Either the HR data were not available or other raw data were
insufﬁcient to conduct a meta-analysis.
(ii) The patients had only received a biopsy or radiochemotherapy.
(iii) The article type was a letter, editorial or review.
2.3. Data extraction and end points
The ﬁrst two authors (Y.Y. and W.X) extracted the data from
each eligible article with a standardized form. Disagreements were
resolved through discussion or consultation with another author
(M.Q). Study designs, patient characteristics, operational deﬁni-
tions, combination therapy, patient outcomes, HR, and 95% CIswere extracted from the articles. We also sent emails to the
corresponding authors requesting missing information, as appro-
priate.
Overall survival (OS) is based on death from any cause.
Progression-free survival (PFS) is the length of time during and
after surgery in which the disease being treated does not get worse.
Data for patients alive without progression were censored on the
date of last follow-up evaluation.
2.4. Statistical analyses
Our primary outcome was the overall survival of the GBM
patients. We conducted meta-analyses when data were available
from more than one study. Hazard ratio (HR) and 95% conﬁdence
intervals presented in the studies were used to estimate the pooled
risk. If the HR was not reported in the article, we used the Engauge
Digitizer 4.1 (QT) to extract the time-to-event data from Kaplan–
Meier survival curves, and estimated the Hazard ratio (HR) and 95%
conﬁdence intervals by the methods recommended by Tierney.8
The heterogeneities of the studies were assessed using Cochran’s Q
statistic and the I2 statistic. When the p value was 0.1 and the I2
value was >50%, the heterogeneity was considered signiﬁcant.
Publication biases were estimated using Egger’s tests, and p values
below 0.05 were considered evidence of publication bias. All p
values were two-sided. All analyses were performed with STATA
version 11 (STATA/SE, College Station, TX). Because the character-
istics of eligible patients, study designs, and usage of valproic acid
were not consistent across the articles, we performed further
subset and sensitivity analyses to explore possible explanations of
heterogeneity and to assess the potential effects of these variables
on the outcomes.
The Newcastle–Ottawa Quality Assessment Scale, which was
recommended by the Cochrane Non-Randomized Studies Methods
Working Group, was used to assess our included studies.
3. Results
3.1. Search results and study characteristics
Fig. 1 shows the ﬂow diagram of the electronic literature search
and selection of articles. A total of 166 unique publications were
identiﬁed after the exclusion of duplicates, and the titles or
abstracts of these articles were examined to exclude unrelated
studies. Ultimately, 53 relevant articles were identiﬁed as primary
studies, and the full texts of these articles were retrieved. Next, we
identiﬁed six studies as eligible for our meta-analysis. The authors
of these studies were contacted for further information if the data
presented in the article was insufﬁcient for our needs, e.g., the
paper reported by Me‘lanie S. M. van Breemen8 only provided K–M
curves, but did not include numbers of patients and the follow-up
time. The meta-analysis was ultimately based on ﬁve studies (this
information is summarized in Table 1). One of the studies was
conducted in North America, one was conducted in Asia, and three
were conducted in Europe. All studies were published recently
(published during 2011–2013).
Table 1 displays the design characteristics of the ﬁve studies
that were included in our meta-analysis. Overall, 1634 patients
were included; all patients had been diagnosed with glioblastoma
multiforme. The largest cohort study was conducted by M. Weller
et al.15 (2011) and included 587 GBM patients. Among the included
studies, 59% of patients received chemotherapy, most of them were
treated with temozolomide, and 94.3% of the patients underwent
radiotherapy. Phenytoin and levetiracetam were the most
commonly used antiepileptic drugs beyond valproic acid used to
treat patients. Only two percent of the total patients had missing
data (Table 2).
Fig. 1. Pooled number of patients and percentage of included studies.
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treatment strategies, e.g., the number of patients that underwent
surgery, radiotherapy or chemotherapy, only two studies described
the VPA schedule. Melissa Kerkhof9 reported using VPA as a ﬁrst-line
anticonvulsant instituted at a maintenance dose of 1000–2000 mg.
Hong-Chieh Tsai10 reported using an initial VPA dose of 400 mg q8h,
with a target serum concentration of 50–100 mg/mL. The last three
trials only provided information about using VPA as an antiepileptic
drug and the period of use (Table 3).Table 1
Flow diagram of the electronic literature search and selection of articles.3.2. Survival analysis and heterogeneity
Of the ﬁve trials, four reported a signiﬁcantly longer survival of
GBM patients who had been treated with VPA after surgery
(Table 1). Not surprisingly, the meta-analysis conﬁrmed the
beneﬁt of treatment with VPA (HR, 0.56; 95% CI, 0.44–0.71). No
statistical heterogeneity between trials was found (p = 0.568),
I2 = 0.0% (variation in ES attributable to heterogeneity). We then
performed a subset analysis comparing VPA vs. non-VPA use and
VPA vs. other AED use; there were four studies included in the
analysis. Glioblastoma multiforme patients using VPA showed a
relatively better outcome when compared to patients using non-
AEDs or other-AEDs. Patients using VPA showed a hazard ratio of
0.74 with a 95% conﬁdence interval of 0.59–0.94 vs. patients using
other-AEDs, and a hazard ratio of 0.66 with a 95% conﬁdence
interval of 0.52–0.84 vs. patients with no AED treatment. No
heterogeneity was found in the subset analysis.
4. Discussion
A total of 1634 patients with a conﬁrmed glioblastoma
multiforme diagnosis were examined in our meta-analysis. Our
goal was to provide a relatable, powerful conclusion about whether
valproic acid could prolong the survival of adults with GBM and to
give guidance for clinical treatment and further study.
Initially, we found distinct evidence of a beneﬁcial effect of
adjuvant VPA therapy (HR = 0.56). However, the primary endpoint
of survival in the included studies was based on different control
groups (non-AED or other AEDs), although no heterogeneity was
found in the main meta-analysis. In Fig. 2, we extracted survival
data from the results section in the abstract, and we deﬁned the
result reported in the abstract as the primary endpoint that the
author wanted to disclose, but the results from Fig. 2 could not
be applied to clinical practice because different control groups
were used. Then, we conducted the sub-group analysis based on
the non-AED and other AEDs groups, which contained more
clinical signiﬁcance. There was obvious evidence that VPA
treatment was beneﬁcial and could prolong the life of patients
with GBM when compared to patients in the non-AED group
(HR = 0.74) and other-AEDs group (HR = 0.66) (Fig. 3).
Valproic acid (approved in 1997) is a well established non-
enzyme inducing antiepileptic drug and is also deﬁned as a second
generation anticonvulsant. The reason that VPA use possibly could
have prolonged the survival time of GBM patients is still unclear.
Patrick Y. Wen11 suggested that VPA could increase the bioavail-
ability of temozolomide by decreasing its clearance by 5%
Table 2
Summary of studies included in the met-analyses and active trials.
Study, year Patientsa VPA schedule; dosage Combination Therapy outcome
Melissa Kerkhof,9 2013 165 Daily; 1000 mg Surgery, RT and
chemotherapy
Patients using VPA in combination with
temozolomide showed a longer median survival of
69 weeks compared with 61 weeks in the group
without VPA (hazard ratio, 0.63; 95% CI: 0.43–0.92;
p = 0.016)
A. Christopher,23 2013 544 VPA uses during RT Surgery, RT and
chemotherapy
Median OS of patients receiving VA and TMZ during
RT was 23.9 months (vs. 15.2 months for patients
using another AED, p = 0.26)
D. Greg,16 2012 236 VPA as AED Unknownb Those treated with VPA had signiﬁcantly longer
survival times than those who did not receive an AED
(Mantel–Cox log-rank test 17.506, p < 0.001), and
patients treated with VPA had signiﬁcantly longer
survival times than those who had received other
AEDs (Mantel–Cox log-rank test 5.303, p < 0.02)
M. Weller,22 2011 587 VPA as AED Surgery, TMZ/RT ! TMZ Patients receiving VPA alone (97 [16.9%]) appeared
to derive more survival beneﬁt from TMZ/RT (hazard
ratio [HR] 0.39, 95% conﬁdence interval [CI]
0.24–0.63) than patients receiving an EIAED only
(252 [44%]) (HR 0.69, 95% CI 0.53–0.90) or patients
not receiving any AED (HR 0.67, 95% CI 0.49–0.93)






Early administration of VPA as an adjunct to GBM
treatment may have its merits (within 14 days,
Hazard ratio and 95% conﬁdence interval 0.598
(0.281–1.272))
Study type Patients (no.; age) VPA schedule; dosage Combination therapy Primary outcome measures
Active clinical trials
Phase II NCT00302159 GBM
(41; adults)
Twice a day during
radiation and
chemotherapy
Radiation therapy Temozolomide Progression-free survival and
Phase II NCT00879437 HGG or brain stem glioma
(56; 3–21 years)
Daily, 85–115 mg/l Radiation therapy (54–59.4 Gy)
Maintenance: bevacizumab
Event-free survival
a All patients were diagnosed with glioblastoma multiforme.
b Data could not be extracted from studies.
Table 3






Melissa Kerkhof9 Cohort **** * **
A. Christopher23 Cohort *** ** ***
D. Greg16 Cohort *** ** ***
M. Weller22 Cohort **** ** ***
Hong-Chieh Tsai10 Cohort *** * **
Fig. 2. Forrest plot of the studies r
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phenytoin or phenytoin and adjuvant TMZ treatment. Another
potential beneﬁt of VPA may be due to its action as a histone
deacetylase (HDAC) inhibitor.12 As a HDAC-inhibiting agent,
valproic acid might enhance the sensitivity of tumor cells to
chemotherapy, arrest cell growth, induce the differentiation or
apoptosis of glioma cells, and improve the survival of patients
when combined with one or more chemotherapeutic agents. In
addition to our included studies, a previously published study also
suggested that VPA could prolong survival. Weller and colleagueseporting a primary outcome.
Fig. 3. Sub-group analysis.
Fig. 4. Schematic illustration of VPA and HDAC’s inﬂuence on cell cycle regulation. ERK: extracellular signal-regulated kinase; HDAC: histone deacetylases. 5-LOX, 5-
lipoxygenase; eNOS, endothelial nitric-oxide synthase; JNK, c-jun N-terminal kinase; VPA: valproic acid.
Y. Yuan et al. / Seizure 23 (2014) 830–835834reported that patients receiving a non-EIAED alone appear to
derive more survival beneﬁt from TMZ/RT (mainly VPA, hazard
ratio [HR] 0.39, 95% conﬁdence interval [CI] 0.24–0.63) than
patients receiving an EIAED alone (HR 0.69, 95% CI 0.53–0.90) or
patients who are not receiving any AEDs (14 months vs. 11 months
HR 0.67, 95% CI 0.49–0.93). Equally intriguing is the autophagy
stimulated by valproic acid. Autophagy represents an alternative
tumor-suppressing mechanism that overcomes the dramatic
resistance of malignant gliomas to radiotherapy and proapopto-
tic-related chemotherapy.13 After years of clinical practice, VPA
has proved to be well tolerated and safe over a wide range of
plasma levels. Sedation, dizziness and tremor are commonneurological side effects.14 Other complications, such as hyper-
ammonemia or hematological toxicity, may occur relatively
frequently, but most patients are mainly asymptomatic.
The results of our analysis should be interpreted with caution,
especially because no revolutionary drugs have been discovered in
recent years for newly diagnosed GBM patients since temozolo-
mide was adopted into clinical practice. Obviously, it would be of
great value to explore the use of valproic acid as a standard
treatment, such as surgery and chemoradiotherapy, in GBM.
However, before VPA can be written into guidelines, several
randomized comparative multicenter clinical studies should be
conducted. At the date of this manuscript, there have been no
Y. Yuan et al. / Seizure 23 (2014) 830–835 835related RCTs published in any journal. However, two phase II trials,
which are registered in clinicaltrials.gov (NCT00302159 and
NCT00879437), are underway (see Table 1). We anxiously await
the results of these international RCTs and hope that the results of
these studies will enhance the treatment of glioblastoma.
Abundant preclinical in vivo and in vitro research has suggested
that VPA can regulate tumor cells in many respects (summarized in
Fig. 4). The most important effect of VPA is the inhabitation of the
HDAC, which subsequently modulates the MAPK signaling
pathway,16 the b-catenin pathway (associated with metastatic
growth of tumor cells)17 and other further pathways.18,19 Thelen P
showed that VPA could particularly induce apoptosis of the cancer
cell line LNCaP.20 It has also been proven that VPA application to
tumor cells can not only generate a decrease of vascular
endothelial growth factor (VEGF) but also lead to down-regulation
of its coding mRNA, which is highly relevant for the treatment of
malignant solid tumors with high neovascularization, such as
glioblastoma multiforme.21
Even though the results from our meta-analysis seem promis-
ing, there were some limitations. Most of the results discussed
were generated through unplanned retrospective analyses. The
selection of the AEDs that were used depended on the investiga-
tors’ preferences and local practices, although we did not ﬁnd
evidence of a bias. However, beyond this limitation, retrospective
studies can be used as a joint analysis to guide us in deciding the
next step of whether to conduct a large-scale RCT investigating the
impact of co-medication with valproic acid in GBM patients.
Progression-free survival (PFS) is another important index for
malignant tumors. However, we evaluated overall survival (OS)
because we could not combine the hazard ratio (HR) of our selected
studies because only one trial reported the PFS. No signiﬁcant
difference in outcome was observed for PFS in the study of M.
Weller.15
Based on previously mentioned promising results from clinical
and preclinical studies, should neurosurgeons treating glioblasto-
ma patients routinely prescribe VPA as a standard of care? The
answer should be interpreted with caution. However, although all
of the included studies are retrospective and may induce
unplanned bias, they at least provide us with a signiﬁcant result
that can be used as guide to move forward to conduct a RCT. A
randomized phase II trial of valproic acid in newly diagnosed
glioblastoma patients should be undertaken.
5. Conclusions
The results of our study suggest that VPA administration to
glioblastoma patients may prolong survival time. Sub-analysis
conﬁrmed the beneﬁt of VPA use when compared to groups of
patients who received non-AEDs and other-AEDs. Further RCTs
exploring the beneﬁts of VPA treatment should be performed.
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